COMBINED TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE

摘要

1. A pharmaceutical composition for the prevention or treatment of COPD, comprising: (a) glycopyrronium chloride; and (b) formoterol or a salt thereof; dissolved in an HFA propellant or in a mixture of an HFA propellant with a co-solvent, adding 1M HCl to the composition in an amount of 0.1-0.3 μg / μl of the composition. 2. The composition of claim 1, wherein the amount of 1M HCl is 0.15 to 0.28 μg / μl. The pharmaceutical composition according to claim 1, wherein the cosolvent is ethanol. The pharmaceutical composition according to any one of the preceding claims, which further comprises one or more pharmaceutically active ingredients selected from the group consisting of beta agonists, corticosteroids, antimuscarinic agents and phosphodiesterase (IV) inhibitors. 5. The pharmaceutical composition according to claim 4, comprising beclomethasone dipropionate. The pharmaceutical composition according to claim 5, wherein the concentration of (a) glycopyrronium chloride is in the range of 0.005-0.83% w / w. The pharmaceutical composition according to claim 6, wherein the concentration (b) of formoterol or its salt is in the range of 0.005-0.07% w / w. The pharmaceutical composition of claim 1, wherein the oxygen has been substantially removed by purging. The pharmaceutical composition of claim 4, wherein the oxygen has been substantially removed by purging. An aerosol container containing a pharmaceutical composition according to any one of claims 1 to 8.11. The container of claim 10, from which oxygen has been substantially removed from the space above the pharmaceutical composition contained therein. The method of filling the container according to claim 10 or 11, comprising the steps of: a) obtaining a solution of glycopyrronium chloride, formoterol fumarate and, optionally, beclomethasone dipropionate in a co-solvent, to which